Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer
PHASE1CompletedINTERVENTIONAL
Enrollment
18
Participants
Timeline
Start Date
August 31, 2004
Study Completion Date
March 31, 2007
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL
trastuzumab
DRUG
imatinib mesylate
Trial Locations (1)
19111-2497
Fox Chase Cancer Center, Philadelphia
All Listed Sponsors
collaborator
National Cancer Institute (NCI)
NIH
lead
Fox Chase Cancer Center
OTHER
NCT00084513 - Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer | Biotech Hunter | Biotech Hunter